Introduction:
After its emergence in Wuhan, Hubei  province of China in December 2019 novel Corona virus disease (COVID-19) infection has grown into one of the largest healthcare crises of the last century. Early reports from China and later Europe indicated that the angiotensin converting enzyme 2 (ACE 2) surface protein acts as a receptor for this virus and is the port of entry for the virus into the cell. These receptors are also expressed in myocardium, reflecting the link between heart and the virus. Emerging data has shown that this novel virus affects the cardiovascular system in several ways leading to increased morbidity and mortality. Several case reports and recently published epidemiological data have shown that patients with myocardial involvement and COVID -19 infection have poor outcomes [1]. The other described effects of this viral infection on the cardiovascular system include myocardial infarction, acute exacerbation of heart failure, arrhythmias and procoagulant effects. The cardiovascular complications related to COVID-19 have led to the need of echocardiographic services for these patients to help with the management and identification of complications. The aim of this study was to identify echocardiographic findings in COVID-19 infection and its utility in management .